Preparation of 3H-23-hydroxylbetulinic Acid and in Vivo Evaluations in Mice

YANG Min,WANG Guangji,XIANG Jingde,XU Yuping,WANG Songpei,LI Xiaomin,PAN Shangren,XU Xijie,YE Wencai
DOI: https://doi.org/10.3321/j.issn:0253-3219.2005.12.010
2005-01-01
Nuclear Techniques
Abstract:The purpose of this work is to study the preparation and pharmacokinetics in mice of tritium-labeled 23-hydroxylbetulinic acid (3H-23-HBA). 3H-23-HBA was synthesized by oxidation with manganese and deoxidization with tritium-labelled sodium borohydride. The purity and stability of 3H-23-HBA were evaluated by HPLC and TLC, and the dynamic distribution in ICR mice and liver cancer HepA tumor-bearing mice were studied. The results showed that the radiochemical purity was over 95% and the specific radioactivity was 3.33×105 Bq/μg (23-HBA); 3H-23-HBA in tetrahydrofuran was stable at –20℃; 3H-23-HBA cleared slowly in blood (MRT=32.68 h) and about 60% of the total radioactivity in plasma was contributed by 23-HBA; and 3H-23-HBA was concentrated in gallbladder, liver and small intestine. In tumor-bearing mice, the uptakes of lung and gallbladder were higher than the normal mice, especially in the gallbladder. At 8 h post intravenous injection, the uptake of gallbladder was still as high as 106.89%±47.4%ID/g organ. The tumor-to-muscle ratio was about 2. The purity of 3H-23-HBA is high and 3H-23-HBA is stable. So 3H-23-HBA appears to be fit for the pharmacokinetic study of 23-HBA.
What problem does this paper attempt to address?